Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.29EUR
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
€75.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,507,244
52-wk High
€84.82
52-wk Low
€62.88

Latest Key Developments (Source: Significant Developments)

Sanofi completes divestiture of Zentiva to Advent
Monday, 1 Oct 2018 01:05am EDT 

Oct 1 (Reuters) - Sanofi ::* Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International, effective September 30. .* The transaction was finalized ahead of schedule for an enterprise value of 1.9 billion euros..  Full Article

Regeneron Pharmaceuticals Inc - FDA Approves Libtayo
Friday, 28 Sep 2018 04:39pm EDT 

Sept 28 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES LIBTAYO® (CEMIPLIMAB-RWLC) AS FIRST AND ONLY TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - U.S. LIST PRICE, OR WHOLESALE ACQUISITION COST, IS $9,100 PER THREE-WEEK TREATMENT CYCLE FOR LIBTAYO.  Full Article

FDA To Review Supplemental Biologics License Application
Wednesday, 12 Sep 2018 08:00am EDT 

Sept 12 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA TO REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR PRALUENT® (ALIROCUMAB) INJECTION AS POTENTIAL TREATMENT TO REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS.REGENERON PHARMACEUTICALS INC - FDA SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF APRIL 28, 2019.  Full Article

Sanofi Launches Drug For Treatment Of Multiple Sclerosis In India
Monday, 6 Aug 2018 01:55am EDT 

Aug 6 (Reuters) - Sanofi SA ::SANOFI LAUNCHES ORAL TABLET AUBAGIO FOR TREATMENT OF MULTIPLE SCLEROSIS IN INDIA.  Full Article

Sanofi And Revolution Medicines Partner To Develop Potential Targeted Treatments For Multiple Cancers
Wednesday, 18 Jul 2018 06:00am EDT 

July 18 (Reuters) - Sanofi SA ::SANOFI AND REVOLUTION MEDICINES LAUNCH GLOBAL PARTNERSHIP TO DEVELOP POTENTIAL FIRST-IN-CLASS TARGETED TREATMENTS FOR MULTIPLE CANCERS.SANOFI -COS EXPECT TO BEGIN FIRST-IN-HUMAN CLINICAL TRIALS WITH RMC-4630 IN SECOND HALF OF 2018.SANOFI - COMPANIES WILL JOINTLY DEVELOP SHP2 INHIBITORS, WHICH ARE DESIGNED TO REDUCE CELL GROWTH SIGNALING THAT IS OVERACTIVE IN CANCER.SANOFI - TO GET EXCLUSIVE WORLDWIDE LICENSE FOR COMMERCIALIZATION OF APPROVED PRODUCTS TARGETING SHP2, SUBJECT TO U.S. CO-PROMOTE OPTION FOR REVOLUTION.SANOFI - IN COLLABORATION, COMPANIES WILL JOINTLY DEVELOP SHP2 INHIBITORS.  Full Article

Sanofi Invests EUR 66 Mln In Chengdu, Sichuan Province, China
Monday, 2 Jul 2018 06:00am EDT 

July 2 (Reuters) - Sanofi SA ::SANOFI TO FURTHER ACCELERATE ITS SCIENTIFIC PRESENCE WITH THE OPENING OF A GLOBAL RESEARCH AND DEVELOPMENT OPERATIONS HUB IN CHENGDU, CHINA.SANOFI - INVESTS EUR 66 MILLION IN CHENGDU, SICHUAN PROVINCE, CHINA.  Full Article

European regulator CHMP approves Sanofi's Cablivi
Thursday, 28 Jun 2018 10:31pm EDT 

June 29 (Reuters) - Sanofi SA ::* The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder..* Cablivi was developed by Ablynx, a Sanofi company.* The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorisation Application for Cablivi in the European Union is expected in the coming months. .  Full Article

Sanofi completes previously announced acquisition of Ablynx
Tuesday, 19 Jun 2018 12:05am EDT 

June 19 (Reuters) - Sanofi ::* Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure .* Sanofi announced 3.9 bln euros takeover of Ablynx back in January nL8N1PO145.  Full Article

Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)
Wednesday, 16 May 2018 01:00am EDT 

May 16 (Reuters) - Sanofi ::* Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis.* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 .* A pivotal Phase 3 trial evaluating Dupixent (®)(dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints.* In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures.* Dupixent is the first and only biologic to show positive results in this patient population, adds Sanofi.  Full Article

Sanofi And Ablynx Announce Commencement Of Squeeze-Out Tender Period
Monday, 14 May 2018 02:00am EDT 

May 14 (Reuters) - Ablynx NV ::SANOFI AND ABLYNX ANNOUNCE THE SUCCESSFUL RESULTS OF THE INITIAL TENDER OFFER PERIOD FOR ABLYNX AND COMMENCEMENT OF SQUEEZE-OUT TENDER PERIOD.ABLYNX NV - SANOFI CONFIRMED THAT MINIMUM TENDER CONDITION AND OTHER CONDITIONS TO OFFERS HAVE BEEN SATISFIE.ABLYNX NV - SANOFI HAS DECIDED TO PROCEED WITH A SQUEEZE-OUT OF THOSE SECURITIES NOT TENDERED TO OFFERS.  Full Article

Photo

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.